<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Transparency of measures regulating the prices of medicinal products for human use (debate) - Monday, 4 February 2013</title><meta name="title" content="Verbatim report of proceedings - Transparency of measures regulating the prices of medicinal products for human use (debate) - Monday, 4 February 2013" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2013 - Source: European Parliament" /><meta name="available" content="04-02-2013" /><meta name="sipade-leg" content="7" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Transparency of measures regulating the prices of medicinal products for human use (debate) - Monday, 4 February 2013" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-7-2013-02-04-ITM-020_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li class="hr" title="hr - hrvatski">hr - hrvatski</li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-7-2013-02-04-ITM-020_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-02-04-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-02-04-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-02-04-ITM-019_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-02-04-ITM-019_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-7-2013-02-04-ITM-021_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-7-2013-02-04-ITM-021_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-02-04_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-02-04_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2012/0035(COD)">2012/0035(COD)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">A7-0015/2013</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/A-7-2013-0015_EN.html" class="ring_ref_link">A7-0015/2013</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p>
                        <a href="/doceo/document/PV-7-2013-02-04-ITM-020_EN.html" class="ring_ref_link">PV 04/02/2013 - 20</a><br />
                        <a class="ring_ref_selected">CRE 04/02/2013 - 20</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p>
                        <a href="/doceo/document/PV-7-2013-02-06-ITM-005-03_EN.html" class="ring_ref_link">PV 06/02/2013 - 5.3</a><br />
                        <a href="/doceo/document/CRE-7-2013-02-06-ITM-005-03_EN.html" class="ring_ref_link">CRE 06/02/2013 - 5.3</a><br />
                        <a href="/doceo/document/CRE-7-2013-02-06-ITM-008-03_EN.html?textTabled=A-7-2013-0015" class="ring_ref_link">Explanations of votes</a><br />
                    </td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p>
                        <a href="/doceo/document/TA-7-2013-0039_EN.html" class="ring_ref_link">P7_TA(2013)0039</a><br />
                    </td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Monday, 4 February 2013 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 20. Transparency of measures regulating the prices of medicinal products for human use (debate)</td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table cellSpacing="0" cellPadding="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:14:13&amp;playerEndTime=20130204-21:57:45" target="_blank"><img width="29" height="20" src="/doceo/data/img/vod_all_speakers_left.gif" border="0" /></a></td><td class="switch_button_pv_cre"><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:14:13&amp;playerEndTime=20130204-21:57:45" target="_blank">Video of the speeches</a></td><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:14:13&amp;playerEndTime=20130204-21:57:45" target="_blank"><img width="5" height="20" src="/doceo/data/img/switch_pv_cre_right.gif" border="0" /></a></td></tr></table></td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table align="right" cellpadding="0" cellspacing="0"><tr><td><a href="/doceo/document/PV-7-2013-02-04-ITM-020_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_left.gif" width="22" height="20" border="0" alt="" /></a></td><td class="switch_button_pv_cre"><a href="/doceo/document/PV-7-2013-02-04-ITM-020_EN.html" title="Minutes">PV</a></td><td><a href="/doceo/document/PV-7-2013-02-04-ITM-020_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_right.gif" width="5" height="20" border="0" alt="" /></a></td></tr></table></td></tr></table>
<a name="1-175-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1941.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:14:16&amp;playerEndTime=20130204-21:14:23" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Presidente. − </span></span>  L'ordine del giorno reca la relazione di Antonyia Parvanova, a nome della commissione per l'ambiente, la sanità pubblica e la sicurezza alimentare, sulla proposta di direttiva del Parlamento europeo e del Consiglio relativa alla trasparenza delle misure che disciplinano la fissazione dei prezzi dei medicinali per uso umano e la loro inclusione nei regimi pubblici di assicurazione malattia (<a href="https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&amp;lg=EN&amp;type_doc=COMfinal&amp;an_doc=2012&amp;nu_doc=0084">COM(2012)0084</a> – C7-0056/2012 – <a href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2012/0035(COD)">2012/0035(COD)</a>) (<a href="/doceo/document/A-7-2013-0015_EN.html">A7-0015/2013</a>).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-176-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/34234.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:14:22&amp;playerEndTime=20130204-21:18:19" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Antonyia Parvanova, </span></span>  <span class="italic">rapporteur</span><span class="bold">. − </span>Madam President, the transparency of measures regulating the pricing and reimbursement of medicinal products in the Union is currently governed by a directive which is almost 25 years old, and the Commission has rightly identified loopholes and delays to be addressed.</p>
<p class="contents">The pharmaceutical market has significantly evolved since 1989, and so have patients’ needs. At the same time, the financial sustainability of national health-care systems has been put under greater pressure by the combined effect of the economic crisis and the ageing of our population, of which we have just spoken. </p>
<p class="contents">I would like to thank you, Commissioner, and your hard-working staff for having presented this legislative proposal and for maintaining a constant dialogue among institutions on this dossier. It was, firstly, essential and fully relevant to include in this proposal the main conclusion of the 2007 pharmaceutical sector inquiry led by DG Competition. </p>
<p class="contents">Furthermore, the delays in the pricing and reimbursement of medicines that have come to light, and which can sometimes reach more than 700 days, are not acceptable. I am convinced that fair practices in our pharmaceutical market would also be beneficial to patients and national healthcare systems. The European Parliament has demonstrated its willingness to play an active role in the drawing up of this legislation with a report strongly supported by the Committee on the Environment, Public Health and Food Safety last December. </p>
<p class="contents">We have also heard the concerns raised by several stakeholders, including national delegations within the Council. We are presenting significant changes to the initial proposal, which included some provisions, such as the pre-notification of draft national measures or the remedies procedures, that did not appear to be proportionate to the objectives pursued. </p>
<p class="contents">Our objective has been to strike a balance between the need to set up common transparency and procedural requirements while guaranteeing legal certainty and flexibility for competent national authorities with one principle in mind: accessibility and affordability of medicines for all.</p>
<p class="contents">We therefore call for clear timelines for the pricing and reimbursement of innovative products, with the opportunity to use health technology assessments. Two other key elements for the financial sustainability of national healthcare systems are the shortened timelines for generic medicines and the non-interference of intellectual property rights with pricing and reimbursement procedures. </p>
<p class="contents">New provisions have also been introduced by the European Parliament for more transparency in the decision-making process with the requirement to publish experts’ names and declarations of interest as well as an annual list of set prices for products. I know that discussions within the Council are more than difficult, and I would like to take this opportunity to reiterate our willingness to engage in a constructive way and to come up with an optimal proposal which could ultimately bring significant progress for the efficiency of national healthcare systems. </p>
<p class="contents">Of course Member States are, and should remain, fully responsible for regulating the pricing and reimbursement of medicines. But this does not change the fact that we need to set transparent and fair rules on how these decisions are taken, since they will affect both the functioning of the internal market and the accessibility and availability of treatment for patients.</p>
<p class="contents">I would like to conclude by thanking all colleagues, and in particular the shadow rapporteurs, for their fruitful cooperation. Let me also thank the Commission as well as the Cyprus and Irish Presidencies for their hard work, which I hope will bear fruit in the future to the benefit of all.</p>
<p class="contents">Thank you very much for your attention. I am very keen to listen to this debate and to be able to take it into account going forward.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-177-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:18:22&amp;playerEndTime=20130204-21:25:33" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Antonio Tajani, </span></span>  <span class="italic">Vicepresidente della Commissione</span><span class="bold">. − </span>Signora Presidente, onorevoli deputati, prima di tutto voglio ringraziare l'on. Parbanova e congratularmi con lei, come voglio ringraziare l'on. Buşoi e congratularmi per le relazioni elaborate.</p>
<p class="contents">Come sapete, l'argomento di cui stiamo discutendo fu oggetto – e l'on. Grossetête lo ricorderà – di una delle domande che mi vennero poste in occasione della mia audizione come possibile Commissario all'Industria e alle imprese. Presi formalmente, di fronte ai parlamentari, l'impegno di rivedere la direttiva durante il mio mandato. Ho mantenuto l'impegno preso di fronte a voi e ho presentato una proposta che ha tre protagonisti che trarranno benefici una volta approvata la proposta di riforma di direttiva dal Parlamento e dal Consiglio. Innanzitutto gli operatori economici, che hanno bisogno di un ambiente più favorevole per sviluppare prodotti farmaceutici innovativi, poi i pazienti, i nostri concittadini, che sono favorevoli a questa proposta perché darebbe un accesso più rapido ai farmaci in un contesto di maggiore tutela della salute pubblica, e infine gli Stati membri, che trarranno vantaggio da questa direttiva perché otterrebbero risparmi significativi sui loro bilanci nazionali grazie all'accesso più rapido ai farmaci generici.</p>
<p class="contents">La proposta iniziale della Commissione è molto ambiziosa, avendo l'obiettivo generale di modernizzare la direttiva sulla trasparenza rendendo più chiare e prevedibili le norme in essa contenute. È importante sottolineare che abbiamo mantenuto lo spirito della direttiva oggi in vigore, adottata nel 1989, e questo significa che la normativa prevede un minimo di procedure e preserva la competenza degli Stati membri nell'organizzazione dei loro sistemi di assicurazione sanitaria, di fissazione dei prezzi e di gestione dei rimborsi. Signora Presidente, vista anche la sensibilità politica e la complessità tecnica della proposta, non ci aspettavamo un percorso facile. Anche gli emendamenti proposti, che contengono compromessi e soluzioni per questioni delicate, rispecchiano queste difficoltà.</p>
<p class="contents">In risposta alla relazione, anche la Commissione è pronta a mostrarsi flessibile riguardo ai temi delicati che sono in gioco, ma è anche importante sottolineare che lo scopo della Commissione è quello di modernizzare la direttiva e non sarebbe quindi accettabile fare un passo indietro rispetto alla situazione odierna. Quindi, noi accogliamo con favore la relazione della commissione per l'ambiente e accettiamo la maggior parte degli emendamenti. Più precisamente, per quanto riguarda i termini temporali, la Commissione può accettare l'emendamento di semplificazione che istituirebbe un termine di 180 giorni per la fissazione dei prezzi e i rimborsi dei farmaci. Riguardo ai farmaci generici, è opportuno ribadire che per questi farmaci è necessario prevedere termini più brevi perché le loro caratteristiche sono già note. L'emendamento ha trovato una soluzione a questa difficile questione. I termini proposti dalla commissione per l'ambiente per i farmaci generici, di 60 giorni, consentirebbero risparmi significativi alla sanità, pur rispettando le diverse regole procedurali in vigore nei differenti Stati membri.</p>
<p class="contents">La Commissione aderisce inoltre in via di principio agli emendamenti della commissione per l'ambiente relativi alla procedura di ricorso e alla procedura di prenotifica. Tuttavia, come vi ho già detto, non intendiamo fare un passo indietro rispetto alla normativa in vigore oggi. Per tale motivo, non possiamo accettare alcuni emendamenti che avrebbero questo effetto o inciderebbero sulla trasparenza e sulla certezza dei processi di fissazione di prezzi e dei rimborsi. Ad esempio, per quanto riguarda l'interpretazione dei termini, la Commissione ritiene necessario avere un intendimento univoco di quello che in essi è compreso per evitare che obblighi amministrativi supplementari, per esempio di pubblicazione, possano essere usati per aggirare la direttiva.</p>
<p class="contents">Un'altra misura intesa a garantire che la direttiva non possa essere elusa, e che secondo noi dovrebbe essere mantenuta, consiste nel prevedere la possibilità di richiedere la fissazione del prezzo e il rimborso in qualsiasi momento. Si tratta degli emendamenti nn. 28, 33, 38 e 40. Infine, anche per quanto riguarda la base giuridica sostengo una base giuridica unica quale votata in commissione JURI.</p>
<p class="contents">Vorrei concludere ringraziandovi tutti quanti. Ritengo che la relazione rappresenti un compromesso equilibrato e pragmatico e mantenga la sostanza della proposta della Commissione che va nella direzione delle richieste del Parlamento. In occasione dell'audizione, rispondendo alla sollecitazione dell'on. Grossetête, io sostenni che bisognava aggiornare, e quindi bisognava andare avanti, e rimango di quella stessa convinzione. Ritornare indietro sarebbe un errore, oltre che inutile. Quindi mi auguro che gli Stati membri tengano in conto queste nostre posizioni e quella del Parlamento, che io ho recepito e recepisco oggi, con la proposta di mediazione e di compromesso che ci è stata illustrata e che condivido.</p>
<p class="contents">Io però chiedo un forte sostegno del Parlamento – come l'ho chiesto per il recepimento nelle prossime prospettive finanziarie di COSME – perché questa direttiva, così come richiestomi da voi, possa essere resa più moderna e più efficace, portando dei vantaggi a dei soggetti come gli Stati membri, i consumatori e anche le imprese che sono quelli ai quali noi ci rivolgiamo e per i quali stiamo lavorando. Io sono convinto che con il vostro aiuto riusciremo a convincere alcuni componenti del Consiglio ad avere una direttiva sulla trasparenza che possa garantire un miglior funzionamento del mercato interno nell'interesse comune delle imprese, dei pazienti e degli stessi Stati membri.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-178-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/38420.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:25:38&amp;playerEndTime=20130204-21:27:16" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Cristian Silviu Buşoi, </span></span>  <span class="italic">Raportor pentru aviz IMCO</span><span class="bold">. − </span>Aş dori să încep prin a o felicita pe doamna Parvanova pentru munca depusă la acest raport. Mă bucur să văd că s-a ţinut cont de avizul Comisiei pentru piaţa internă şi ţin să-i mulţumesc raportoarei pentru acest lucru, în numele colegilor mei din această comisie. </p>
<p class="contents">Asigurarea accesului la medicamente inovatoare necesită certitudine juridică şi predictibilitate pentru producătorii de medicamente şi acest lucru înseamnă, în primul rând, transparenţă în luarea deciziilor de stabilire a preţului sau de includere în sistemul de asigurări de sănătate. E nevoie de respectarea unor termene în luarea deciziilor, care până acum nu au fost întotdeauna respectate. Interzicerea reevaluării aspectelor care fac obiectul evaluării în vederea autorizaţiei de punere pe piaţă şi introducerea unor termene destul de competitive, dar şi flexibile în acelaşi timp, atât pentru companii, cât şi pentru autorităţile naţionale, reprezintă un important pas înainte.</p>
<p class="contents">Toţi trecem printr-o perioadă dificilă de consolidare bugetară, dar tergiversarea deciziilor de stabilire a preţului şi de includere în sistemul de asigurări nu poate fi o strategie legitimă, ci una iresponsabilă şi contraproductivă pentru pacienţii europeni. De aceea, îmi exprim speranţa că vom reuşi să ajungem la un acord cu Consiliul, care să elimine problemele cu care ne confruntăm în prezent şi care să facă ca această directivă să funcţioneze aşa cum trebuie în toate ţările Uniunii Europene şi, în plus, pacienţii europeni să beneficieze la timp, într-un cadru stabil şi transparent, de medicamente inovatoare.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-179-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/39916.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:27:24&amp;playerEndTime=20130204-21:31:19" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Zofija Mazej Kukovič, </span></span>  <span class="italic">v imenu skupine PPE</span><span class="bold">. – </span>Poročilo prinaša pomemben premik k hitrejšemu dostopu zdravil za paciente, prinaša premik k enotnemu trgu tudi na področju zdravil.</p>
<p class="contents">Države članice imajo različne čase vstopa novih zdravil na trg zaradi številnih ovir. Vse to pa slabša varnost pacientov in daje nejasne razvojne signale tudi industriji.</p>
<p class="contents">Jasni signali lahko spodbudijo centre odličnosti k poglobljenim raziskavam v smeri večjega obvladovanja bolezni. Prav poglobljene raziskave so nujne tudi zaradi demografskih sprememb.</p>
<p class="contents">Cilj poročila je tudi poenostavitev postopkov in javnost podatkov o inštitucijah in strokovnjakih, ki odločajo o vstopu zdravil v sisteme javnega zdravstva.</p>
<p class="contents">Evropska komisija je pripravila predlog direktive, ki je nekoliko preveč ambiciozen, tako za Parlament kot za države članice. Poročilo poročevalke, ki je pred nami, pa je uravnotežen dokument, tako za paciente, države članice in industrijo.</p>
<p class="contents">Kot nekdanja ministrica za zdravje se še posebej spominjam zapletenosti postopkov in dolgih rokov pri vstopu zdravil na trg. Predolgi, tako za paciente kot za industrijo, so bili ti roki. Zato je izboljšava dvajset let stare direktive nujna.</p>
<p class="contents">Pomembno je razumeti tudi skrb držav članic in zdravstvenih blagajn. Ob današnjem dnevu in razpravi, ki je tudi simbolična, zato ker obeležujemo svetovni dan raka, tudi zato se moramo posebej zavedati, kako pomembna je hitra in pregledna dostopnost do zdravil, zdravil, ki rešujejo življenja.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-180-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96603.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:31:27&amp;playerEndTime=20130204-21:33:41" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nessa Childers, </span></span>  <span class="italic">on behalf of the S&amp;D Group</span><span class="bold">. – </span>Madam President, current legislation in this area from 1989 no longer reflects the increased complexity of pricing and reimbursement procedures in Europe. Of course there is a difficult balance between Member States’ right to organise their public health systems, the need for a sustainable pharmaceutical sector and the interests of patients. I believe we must respect and defend national health authorities’ right to organise their own health systems, understand the diversity in European health systems and recognise the current difficult economic context. I do not believe the EU should be facilitating the pharmaceutical industry if this comes at the expense of good public health procedures and sustainable public health budgets.</p>
<p class="contents">Thankfully, many concerns we had on the proposal have now been removed or addressed in a substantial way. Firstly, contrary to its title, the proposal failed to make transparent the real prices paid across the EU, or which patients are getting access to which medicines. Without knowing what others are paying, Member States are not empowered to negotiate for the lowest price. Informed price negotiation can be an effective way to control expenditure. That is why I am happy that the committee vote reinstated the legal basis for the EURIPID database. This is not a public database, but it is used by over 20 Member States themselves to aid their decision-making on medicine pricing.</p>
<p class="contents">Another main issue was the unrealistic time limits on pricing and reimbursement. In the committee vote we have reversed this reduction for originator medicines and doubled the proposed generic time limits. This is a major improvement on the Commission proposal. The proposal for sanctions and penalties on Member States for missing the time limits has been removed. We also voted for a stop-the-clock process which triggers negotiations if the Member States request more information from the company. Again, this is a major improvement on the Commission proposal. </p>
<p class="contents">I would like to thank all colleagues who have worked on this report.</p>
<p class="contents"><span class="italic">(The speaker agreed to take a blue-card question under Rule 149(8)).</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-181-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2278.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:33:47&amp;playerEndTime=20130204-21:34:25" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Paul Rübig (PPE), </span></span>  <span class="italic">Frage nach dem Verfahren der blauen Karte</span><span class="bold">. – </span>Meine Frage bezieht sich auf die Auswirkung der Preisgestaltung auf die Beschäftigung in diesem Sektor. Wie, glauben Sie, wirkt sich hier die Preisbildung auf die Beschäftigung – vor allem von selbstständigen Frauen – aus, und welche Möglichkeiten kann die Preisbildung geben, in diesem Bereich ordentliche Löhne zahlen zu können?</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-182-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96603.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:34:10&amp;playerEndTime=20130204-21:34:48" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nessa Childers (S&amp;D), </span></span>  <span class="italic">blue-card answer</span><span class="bold">. – </span>That is a difficult question to answer. I would have to know what you expect the answer to be, in a sense. I would hope that it would not affect employment, but I think you have to balance that against the public health issues and the issues of the pricing for national government. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-183-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/113487.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:34:57&amp;playerEndTime=20130204-21:36:40" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alda Sousa, </span></span>  <span class="italic">em nome do Grupo GUE/NGL</span><span class="bold">. – </span>Todos os meses os cidadãos gastam uma fatia substancial do salário ou das reformas na compra de medicamentos e questionam-se sobre o preço que pagam, sobretudo em tempos de crise e austeridade. Por isso é tão importante que o processo e as regras de fixação do preço sejam claras e transparentes. Todos queremos saber o quê e porquê estamos a pagar. Mas chegamos hoje a plenário com uma proposta que, apesar das melhorias no relatório, colide com o interesse dos cidadãos e das cidadãs europeus, ao invés de os proteger, como se esperaria, impedindo mesmo os Estados-Membros de reavaliarem a segurança, a eficácia e a qualidade dos medicamentos. </p>
<p class="contents">Além disso, ao estabelecer os prazos para os Estados-Membros decidirem sobre o preço e sobre o sistema de reembolso de cada medicamento, esta diretiva acaba por propor uma ditadura da indústria farmacêutica porque, se os países não o fizerem dentro dos prazos, têm de pagar à indústria, indo ao ponto de consagrar a possibilidade de o fabricante poder impor unilateralmente o seu preço aos Estados-membros caso os prazos não sejam respeitados. </p>
<p class="contents">Para nós isto é inaceitável. Por isso o meu grupo traz a plenário um conjunto de alterações para repor as competências dos Estados-Membros e impedir as penalizações que iriam afetar os serviços públicos de saúde, já tão atacados em tempos de austeridade e com orçamentos minimais, e também no sentido de garantir verdadeiramente os interesses dos cidadãos.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-184-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2025.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:36:46&amp;playerEndTime=20130204-21:39:21" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Françoise Grossetête (PPE). - </span></span>  Madame la Présidente, je voudrais tout d'abord saluer le travail qui a été mené par notre rapporteur, et qui était quand même assez difficile.</p>
<p class="contents">Mais je voudrais aussi exprimer mon regret, car les délais n'ont pas été raccourcis, comme je l'aurais souhaité, et comme la proposition de la Commission, d'ailleurs, le demandait, puisque cette proposition initiale de la Commission européenne était beaucoup plus ambitieuse que ce que nous avons aujourd'hui. En effet, pour les médicaments princeps, il était prévu que les délais soient réduits à soixante jours pour la fixation des prix et soixante jours pour le remboursement. Or, malheureusement, nous sommes revenus aux chiffres de 1989, c'est-à-dire 90 jours.</p>
<p class="contents">Il en est de même pour les médicaments génériques. Nous voulions un délai raccourci à quinze jours et, malheureusement, nous avons un délai de trente jours.</p>
<p class="contents">Alors, puisque nous n'avons pas pu gagner sur les délais, il est important que nous puissions vous soutenir, Monsieur le Commissaire, comme vous nous l'avez demandé, pour que les États membres ne voient pas dans cette directive une velléité de réduire leurs compétences mais simplement la volonté de garantir des conditions d'harmonisation afin d'éviter des pratiques déloyales et des barrières aux marchés, et aussi d'assurer à des millions de patients un accès rapide à des médicaments innovants. C'est pour cela qu'il faudra bien évidemment, prévoir des sanctions lorsqu'il y aura des retards injustifiés.</p>
<p class="contents">Nous devons aussi éviter toute surcharge administrative inutile ou tout double emploi. Les États membres doivent veiller à ne pas remettre en cause les éléments essentiels de l'autorisation européenne de mise sur le marché, tels que la qualité, la sécurité, l'efficacité, la bioéquivalence, la biosimilarité lors du processus de fixation du prix et du remboursement. Une telle attitude serait inacceptable et préjudiciable aux efforts qui sont menés dans la recherche, l'innovation et le développement et remettrait en cause le rôle important de l'Agence européenne des médicaments. </p>
<p class="contents">N'oublions pas que la santé ne doit pas être considérée comme un coût, mais bien comme un investissement à l'égard de nos populations et aussi à l'égard de nos industries de recherche.</p>
<p class="contents">En conclusion, Monsieur le Commissaire, vous avez tout notre soutien.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-185-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96989.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:39:24&amp;playerEndTime=20130204-21:40:59" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Andrés Perello Rodríguez (S&amp;D). - </span></span>  Señora Presidenta, creo que la señora Parvanova y los portavoces han hecho un trabajo importante, tanto por aquellas cosas que proponen quitar del documento inicial como por las que añaden. A mí me parece un acierto que se suprima la fijación de plazos irrealizables y la propuesta de una comisión de autosanción a los Estados para que se denuncien a sí mismos, se sancionen y acaben indemnizando a las empresas farmacéuticas. Porque era una cuestión que solo beneficiaba a la industria y no beneficiaba ni a los pacientes ni a los Estados.</p>
<p class="contents">Por otra parte, introducir la definición de sectores vulnerables, incluyendo a los niños, a los jubilados, a los desempleados y a los enfermos crónicos, y hacer que se tengan en cuenta a la hora de fijar precios y de introducir o quitar medicamentos de los sistemas de seguridad social, es muy importante, sobre todo en momentos de austeridad salvaje en Europa y en momentos de recortes absolutamente inhumanos en los países del sur de Europa que están afectando en materia sanitaria a los más vulnerables. </p>
<p class="contents">Ahora hace más falta que nunca tener en cuenta a esos sectores a la hora de plantear el precio, especialmente en los genéricos, y de plantear qué medicamentos se introducen o no. Evidentemente, sería mucho mejor que llegáramos a ser capaces de tener un sistema de salud similar para todos y que algún día la salud de los europeos esté por encima de espurios intereses financieros e, incluso, de la subsidiariedad. </p>
<p class="contents">Quizá ese día seamos todos más iguales y quizá ese día, incluso, los Gobiernos de los Estados de Europa sean un poco más humanos. La salud no es cualquier cosa, no tiene que estar al albur solo de las crisis financieras. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-186-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:40:58&amp;playerEndTime=20130204-21:41:12" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="italic">Procedura "catch the eye"</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-187-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/113883.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:41:11&amp;playerEndTime=20130204-21:42:25" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Erik Bánki (PPE). - </span></span>  Tisztelt elnök asszony! Üdvözlöm az előttünk fekvő jelentést. Köszönöm szépen Parvanova asszonynak, a jelentéstevőnek, hogy az általunk felvetett javaslatok jó része bekerült a jelentésbe. Örülök annak, hogy a bizottsági javaslatban szereplő, szerintünk túl rövid határidők meghosszabbításra kerültek. Örülök annak, hogy megszűnik a kötelezettség, miszerint minden intézkedést három hónappal a tervezett bevezetést megelőzően be kell jelenteni a Bizottságnak, lehetővé téve ezáltal, hogy indokolt esetben a tagállamok állampolgárai számára kedvező döntéseket hozzanak a kormányok.</p>
<p class="contents">És végül örömömet szeretném kifejezni amiatt, hogy a 15. cikke a) pontja alatt szerepel: a Bizottságnak és a tagállamoknak azt is meg kell vizsgálniuk, miként folytassák az együttműködést az EURIPID tájékoztatási adatbázis fenntartásáról. Meggyőződésem, hogy ez a program nagy mértékben lehetővé teszi és segíti a tagállamok tájékozódását az árak tekintetében és segíti az árak képzésének az összehangolását. Büszke vagyok arra, hogy ez a program magyar részvétellel jött létre a magyar egészségbiztosítási pénztár által, és ebben sok tagállam részt vesz. Szeretnénk, ha a Bizottság fenntartaná továbbra is a támogatást, hiszen anélkül nem tud működni a rendszer. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-188-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28178.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:42:41&amp;playerEndTime=20130204-21:43:50" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Miroslav Mikolášik (PPE). - </span></span>  Zdravie je jedným zo základných cieľov všetkých politík Únie. Prístup k liekom patrí medzi základné atribúty, ktoré vedú k jeho naplneniu, pretože ochrana ľudského života musí stáť za každých okolností na prvom mieste. Je, samozrejme, dôležité, aby sa zabránilo zbytočným prieťahom, to je kľúčové slovo v rozhodovaní o cenách jednotlivých liekov, aby sa jednoducho urýchlilo odstraňovanie aj prekážok v obchode s liekmi. Súhlasím so zavedením minimálnych procedurálnych pravidiel, ktoré by upravovali prístup k liekom na celoeurópskej úrovni, s cieľom zjednodušiť prístup k vzostupnej liečbe pre všetkých pacientov v Európe. To si vyžaduje aj ich dodržiavanie, čím sa zabezpečí transparentnosť a právna istota. Samozrejme, že podporujem a trvám na tom, že aj v tejto oblasti platí subsidiarita a že zdravotníctvo patrí do suverénnej právomoci členských štátov, ale je neprípustné, aby ceny liekov boli v Európskej únii tak rozdielne od jedného štátu k druhému. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-189-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96823.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:44:00&amp;playerEndTime=20130204-21:45:20" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Petru Constantin Luhan (PPE). - </span></span>  Sănătatea reprezintă, fără îndoială, o prioritate majoră pentru cetăţenii Europei şi orice medicament autorizat în Uniunea Europeană ar trebui să fie inclus în sistemele publice de asigurări şi să fie disponibil pentru pacienţii din toate statele membre ale Uniunii Europene. Şi totuşi, românii, spre exemplu, au cel mai mult de suferit dintre toţii pacienţii din ţările Uniunii Europene, din cauza faptului că listele de medicamente compensate nu au mai fost actualizate de peste 1 600 de zile, cea mai lungă perioadă scursă într-un stat membru.</p>
<p class="contents">Sunt multe de discutat pe această temă, dar aş vrea să pun accent pe două elemente extrem de importante: </p>
<p class="contents">1. consider că organizaţiile de pacienţi ar trebui să aibă dreptul să solicite iniţierea procesului de includere a unui medicament în sistemele de asigurări de sănătate şi de a fi informaţi despre progresele înregistrate în acest proces;</p>
<p class="contents">2. Comisia Europeană ar trebui să se implice în monitorizarea şi detectarea întârzierilor în ceea ce priveşte accesul pacienţilor la medicamente şi tratament. Este esenţială, în acest sens, o cooperare strânsă între Comisie, autorităţile naţionale şi părţile interesate.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-190-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23894.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:45:26&amp;playerEndTime=20130204-21:46:33" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Anna Záborská (PPE). - </span></span>  Na Slovensku prebieha verejná diskusia o registrácii potratových tabletiek. Boli sme svedkami toho, ako štátne orgány najskôr neinformovali verejnosť a potom zámerne uvádzali a dodnes uvádzajú nesprávne a nepravdivé informácie. Verejnosť nie je informovaná ani o prípadnom konflikte záujmov u tých, ktorí o liekoch rozhodujú. Preto podporujem opatrenia, ktoré povedú k väčšej transparentnosti. Členské štáty majú právo aj povinnosť zabezpečiť pre svojich občanov kvalitné lieky za cenu, ktorá zohľadňuje kúpnu silu. Nová smernica vnesie viac svetla do rozhodovania regulačných orgánov, ktoré rozhodujú o uvedení liekov na trh, o ich cene a miere dotácie z verejných zdrojov. To je dôležité nielen z pohľadu jednotného európskeho trhu, je to predovšetkým dôležité pre záujem občanov. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-191-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96814.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:46:39&amp;playerEndTime=20130204-21:47:51" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Elena Băsescu (PPE). - </span></span>  În ultimii 20 de ani, condiţiile de pe piaţa farmaceutică s-au schimbat într-un mod fundamental. Ca rezultat al cercetării şi inovării sporite, producţia de medicamente a evoluat considerabil. Creşterea constantă a cheltuielilor farmaceutice din ultimele decenii a încurajat statele membre să elaboreze metode de reglementare a preţurilor şi de rambursare mult mai complexe şi mai inovatoare. </p>
<p class="contents">De aceea, susţin propunerea raportoarei de a actualiza cadrul legislativ existent. Astfel, vom putea reduce barierele din calea comerţului intracomunitar cu produse medicamentoase, asigurând o mai bună funcţionare a pieţei unice. Noile prevederi trebuie să încurajeze dezvoltarea de noi produse farmaceutice şi să sporească transparenţa în procesul decizional. Eliminarea distorsiunilor va aduce beneficii majore companiilor farmaceutice, iar scopul final trebuie să fie facilitarea accesului la tratament şi preţuri rezonabile pentru toţi cetăţenii Uniunii.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-192-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96706.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:47:59&amp;playerEndTime=20130204-21:49:22" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">João Ferreira (GUE/NGL). - </span></span>  Os Estados-Membros são responsáveis pela organização dos respetivos sistemas de saúde e pela repartição dos recursos que lhe são afetados, incluindo na área dos medicamentos. Assim é, e assim deve continuar a ser. É, por isso, ilegítima a ação da Troica ocupante em Portugal, forçando o aumento do preço dos medicamentos e a redução da comparticipação do Estado. O resultado: graves limitações no aceso aos medicamentos. Muitos utentes, especialmente os idosos de mais baixos rendimentos, têm de optar: ou os medicamentos na farmácia ou os alimentos. Alguns hospitais já não disponibilizam os medicamentos aos utentes nas farmácias hospitalares. Quanto a preocupações da Comissão Europeia quanto ao acesso dos doentes aos medicamentos estamos, por isso, conversados. A preocupação que aqui prevalece é outra: o mercado, sempre o mercado, o comércio de medicamentos, os interesses das empresas farmacêuticas. </p>
<p class="contents">Para terminar, um esclarecimento: em Portugal ainda temos um <span class="italic">Serviço Nacional de Saúde, </span>de acordo com a Constituição universal e tendencialmente gratuito. Seria, por isso, conveniente corrigir a expressão utilizada pela Comissão Europeia, <span class="italic">Sistema Nacional de Seguro de Saúde</span>. É que os desejos e as intenções de alguns ainda não são realidade e, no que depender de nós, nunca virão a ser.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-193-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96654.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:49:27&amp;playerEndTime=20130204-21:50:41" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jaroslav Paška (EFD). - </span></span>  Stanovenie ceny lieku, ale aj výšky úhrady zo zdravotného poistenia či výšky doplatku pacienta je mimoriadne dôležitým procesom. Kompetentní rozhodujú o dostupnosti daného lieku v príslušnej krajine a tým aj o zdraví, kvalite či dĺžke života konkrétnych ľudí. Skúsenosti z farmaceutického trhu svedčia o tom, že lehoty na stanovenie cien liekov a úhrad sa v praxi nie vždy dodržiavajú a skutočný prístup na trh sa značne odlišuje nielen medzi jednotlivými členskými štátmi, ale dokonca aj v rámci jedného štátu. Signalizuje je to potrebu nielen nastavenie objektívnych, čestných a spravodlivých kritérií pre uvádzanie liekov na trh, ale súčasne zavedenie účinných kontrolných mechanizmov. Zavedenie väčšej transparentnosti do procedúr a kritérií v oblasti registrácie, kategorizácie a stanovenia úhrady liekov musí byť realizované tak, aby mali všetci výrobcovia rovnaké podmienky pre zaradenie svojich liekov do príslušného systému zdravotného poistenia. Jedine otvorenosťou a korektnosťou liekovej politiky môžeme zlepšiť dostupnosť potrebných liekov pre našich občanov. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-194-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96803.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:50:46&amp;playerEndTime=20130204-21:51:47" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Zbigniew Ziobro (EFD). - </span></span>  Pani Przewodnicząca! Stabilność i bezpieczeństwo systemów ochrony zdrowia łączą się bezpośrednio z dostępem do dobrych i skutecznych leków. Europejskie społeczeństwo niestety starzeje się. To oznacza, że coraz większą pozycję w budżecie, zwłaszcza starszych Europejczyków, będzie zajmować wydatek na leki. Niestety obserwujemy, że niektóre firmy farmaceutyczne wykorzystują swoją dominującą pozycję, śrubując ceny leków na różnym poziomie w różnych krajach Unii Europejskiej. Co więcej, dochodzą nawet sygnały o korupcyjnych praktykach, próbach oddziaływań na decydentów, którzy decydują, że pewne leki określonych firm są refundowane, inne – nie. </p>
<p class="contents">W Polsce, na przykład, dużym echem odbiła się sprawa refundacji leków dla cukrzyków i spowodowało to duże poruszenie opinii publicznej. Dlatego też przejrzystość i jasność w tym obszarze jest niezwykle ważna, ale trzeba się również zastanowić nad zapobieganiem mechanizmom korupcyjnym, które – z uwagi na pokusę ogromnych pieniędzy – też pojawiają się w związku z działalnością firm farmaceutycznych.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-195-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:51:45&amp;playerEndTime=20130204-21:51:59" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="italic">(Fine della procedura "catch the eye")</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-196-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Antonio Tajani, </span></span>  <span class="italic">Vicepresidente della Commissione</span><span class="bold">. −</span> Signora Presidente, onorevoli deputati, molti hanno sottolineato, anche con qualche tono un po' di rimprovero, quanto la Commissione sia stata ambiziosa nel presentare la proposta di riforma della direttiva. Sì, forse siamo stati ambiziosi, sono stato ambizioso, e la critica peraltro compensa le altre critiche che ci arrivano quando il Parlamento dice che la Commissione non è sufficientemente ambiziosa. Questa volta, invece, siamo andati avanti. Io credo di poter dire, però, che mai mi ha sfiorato il pensiero di violare il principio di sussidiarietà, nel quale mi riconosco e che rispetto e considero fondamentale per la nostra Unione europea. Direi che siamo comunque sempre stati, anche nel testo originale, entro i limiti di rispetto di questo principio così importante.</p>
<p class="contents">Però non posso, in conclusione di questo dibattito, non ribadire la mia totale disponibilità ad accettare il testo di compromesso elaborato con il coordinamento del relatore on. Parvanova. Quindi, come ho detto in apertura del dibattito, per la Commissione europea le proposte della relatrice sono positive. Quando si cerca di essere ambiziosi poi il compromesso ti porta a essere comunque nel giusto. Se non fossi stato ambizioso nella mia proposta, forse oggi staremmo a discutere di un testo meno utile per i nostri cittadini, le nostre imprese e per i nostri Stati membri. Credo che se questo testo verrà poi approvato dal Consiglio – e rispondo alla sollecitazione che era stata fatta dall'on. Rübig con la <span class="italic">blue card</span> – porterà certamente vantaggi anche all'occupazione. Quindi si tratta di un testo che va verso molte direzioni, ma soprattutto va nella direzione della tutela degli interessi dei nostri concittadini.</p>
<p class="contents">COMMISSION POSITION ON THE EUROPEAN PARLIAMENT AMENDMENTS</p>
<p class="contents">The Commission can accept Amendments 2, 5, 6, 9, 12, 19, 24, 34, 37, 38, 39, 43, 49, 51, 57, 58, 59.</p>
<p class="contents">The Commission can accept Amendments 3, 7, 10, 11, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 25, 26, 28, 29, 30, 31, 32, 33, 35, 40, 41, 42, 44(1), 45, 46, 48, 53, 54, 55, 56 in principle.</p>
<p class="contents">The Commission cannot accept Amendments 1, 4, 8, 27, 36, 44(2), 47, 50, 52, 60, 61, 62, 63, 64.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-197-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/34234.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:54:38&amp;playerEndTime=20130204-21:57:33" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Antonyia Parvanova, </span></span>  <span class="italic">rapporteur</span><span class="bold">. −</span> Madam President, let me first thank you for all your contributions tonight. Our debate demonstrates that we are fully committed to making progress on this proposal. I hope that our vote on Wednesday will send a clear and constructive message to the Commission and especially to the Council. </p>
<p class="contents">Just one word ahead of this vote, regarding Amendment 1 from the Committee on the Environment, Public Health and Food Safety (ENVI) which introduces a dual legal basis for the proposed directive. While recognising a public health dimension, I would recommend that we follow the opinion of the European Parliament’s Legal Service and that of the Committee on Legal Affairs (JURI) and stick to the single legal basis proposed by the Commission. </p>
<p class="contents">I fully understand some of the concerns raised tonight and I am confident that a continued dialogue amongst the institutions is the solution towards achieving an optimal legislative framework which would respond to the needs of all stakeholders involved, whether they are patients or authorities or pharmaceutical companies. But we have to bear in mind that the timelines – an ambitious proposal, in fact – are crucially important for the accessibility of drugs. </p>
<p class="contents">I would also like to mention that while working on the clinical trials directive I have noticed that there are shorter timelines in the clinical trials for the committees to decide whether a drug should be registered, in comparison with the timelines that the same or other authorities – with the same experts – need just to register a price or just to register a drug and put it on a list for reimbursement. I believe that there should be some fairness and parity in this. </p>
<p class="contents">I believe that the status quo is not the answer, and just looking back at some recent developments at national level we have seen issues raised in France regarding the reimbursement of products for which the therapeutic added value and the safety profile have been seriously questioned. We still have numerous cases of patent linkage delaying the entry of generics in Portugal, and last week the Commission sent an objection following the pay-for-delay case and anti-competitive practices in pharmaceutical companies observed in the Netherlands. These recent cases are yet more evidence that the EU proposal bringing more transparency to the pricing and reimbursement of medicines has concrete added value and we need fair, transparent and evidence-based decisions for our healthcare systems in Europe. </p>
<p class="contents">I hope that all the institutions will be willing to engage in this direction and that citizens and patients can count on the European Parliament to maintain these principles in our future decisions. I would like to thank the Commissioner for his very ambitious proposal. If we had a more tolerant and engaged Council I would have been even more ambitious than you.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-198-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1941.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20130204-21:57:32&amp;playerEndTime=20130204-21:58:07" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Presidente. − </span></span>  La discussione è chiusa.</p>
<p class="contents">La votazione si svolgerà mercoledì 6 febbraio 2013.</p>
<p class="contents"><span class="bold"><span class="italic">Dichiarazioni scritte (articolo 149)</span></span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-198-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23938.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">John Attard-Montalto (S&amp;D), </span></span>  <span class="italic">in writing. </span><span class="bold">– </span>Since the beginning of this legislature I have been campaigning for transparency in medicine prices. In Malta the price of medicines is very high. This is often explained as being due to the small domestic market and transportation costs. This is true, but these arguments are also used as camouflage to explain the extraordinary high prices of medicine. Medicines in Malta usually cost twice as much as they do in Belgium. In many cases they cost even more than this. There are a number of medicine importers. It is supposed to be a competitive market. But the question is, how competitive is this market in reality? Why does the government tolerate such a situation? Is there a political will to do something meaningful? Notwithstanding the public awareness campaign which I have undertaken and the discussions held with the importers of medicine in Malta, only a limited percentage of the 2 500 medicines on sale have had their prices reduced. The government in office has lost a golden opportunity on a bipartisan issue. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-198-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/21818.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Paolo Bartolozzi (PPE),</span></span>  <span class="italic"> per iscritto. </span><span class="bold">– </span>Quella relativa alla trasparenza delle misure che disciplinano la fissazione dei prezzi dei medicinali per uso umano e la loro inclusione nei regimi pubblici di assicurazione malattia è una direttiva estremamente importante che, alla luce delle evoluzioni intercorse nel settore, ha risposto alla necessità di aggiornare il quadro normativo attualmente in vigore il quale, sebbene abbia avuto un impatto estremamente positivo, non riesce più a soddisfare le esigenze dalle quali era nato.</p>
<p class="contents">In questo senso il progetto di relazione in esame, pur nel pieno rispetto della competenza esclusiva detenuta dagli Stati membri in materia, si è proposto di delineare una cornice in grado di garantire l'applicazione di norme trasparenti e adeguate alle misure adottate a livello nazionale in materia di fissazione dei prezzi e di rimborso, con il fine ultimo di facilitare l'acceso a cure più sostenibili per i pazienti e di incoraggiare al tempo stesso la ricerca per nuovi medicinali. Un approccio questo che ci auguriamo verrà mantenuto in tutte le prossime fasi negoziali.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-198-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/102886.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ildikó Gáll-Pelcz (PPE), </span></span>  <span class="italic">írásban. </span><span class="bold">– </span>Jómagam is figyelemmel követtem e jelentést, s megvallom, határozottan egyetértek Parvanova asszony azon meglátásával, hogy e javaslat legfőbb célkitűzése a meglévő jogi keret módosítása kell, hogy legyen. Úgy gondolom ugyanis, hogy nagyon fontos a tagállamokra rótt eljárási kötelezettségek tisztázása, valamint az egységes piac megfelelő működésének és a belső piaci jogszabályok hatékonyságának biztosítása annak érdekében, hogy mind az ármegállapítási és ártámogatási döntések késedelmét megakadályozhassuk, mind pedig a gyógyszer-kereskedelmet gátló akadályokat elháríthassuk. Úgy vélem továbbá, hogy az arányosság létfontosságú az ebben az irányelvben előirányzott intézkedések gyakorlatias és ésszerű végrehajtásának biztosításához. A generikus gyógyszerekre vonatkozó határidők javasolt meghosszabbításával összhangban az a meglátásom, hogy a megszavazott szakbizottsági módosító indítványokkal szavatolni tudjuk majd az előirányzott rendelkezések gyakorlati és eredményes végrehajtását, valamint ezáltal is biztosítani tudjuk a nemzeti illetékes hatóságok számára az ezen irányelv követelményeinek való megfeleléshez szükséges mértékű rugalmasságot és önállóságot. Üdvözlöm tehát a jelentést, köszönöm bolgár képviselőtársam munkáját, s mindenkit arra kérek, hogy a szavazáson is támogassa e nagyszerű jelentést.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-198-906"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96999.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alexander Mirsky (S&amp;D), </span></span>  <span class="italic">in writing. </span><span class="bold">– </span>Nowadays the pharmaceutical industry has become a business. The maximum amount of money is squeezed from ill people for low-price medicines. That business has turned into cynicism and impudence on the side of producers and retailers. Mass advertising misleads people. But the results brought by medicines are sometimes tiny. It is necessary as soon as possible to organise control over price production (the price should not be higher than 20 % of net cost), to establish strict supervision of quality, efficiency and side effects. We altogether should say ‘No’ to the black cloud from the side of pharmaceutical companies and monopolists. Those using the ignorance of EU citizens for their own benefit should be deprived of licences and producers’ rights.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="1-198-937"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28177.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Bernadette Vergnaud (S&amp;D), </span></span>  <span class="italic">par écrit. </span><span class="bold">– </span>Madame la Présidente, chers collègues, je suis rassurée sur le texte que nous allons voter, car la proposition initiale de la Commission faisait le jeu de la rentabilité des laboratoires au détriment de l'équilibre budgétaire des systèmes d’assurance-maladie. Le seul argument de mettre les nouveaux médicaments plus rapidement à disposition des patients ne tient pas, et l'introduction de nouveaux délais de traitement des demandes considérablement raccourcis, irréalistes et assortis d'une clause d'acceptation tacite du prix demandé par le laboratoire en cas de non-respect des délais était disproportionnée. Je me félicite donc que plusieurs de mes propositions aient été reprises dans le texte et votées par la commission de l'environnement. Nous avons pu allonger les délais, ce qui rend le texte acceptable. En revanche, la clause d'acceptation tacite n'a été supprimée que pour les demandes d'augmentation de prix, ce qui est regrettable. Enfin, il est très positif que nous soyons parvenus à garantir la possibilité pour les Etats membres de réévaluer l'efficacité relative d'un médicament par rapport à d'autres traitements afin de décider de son remboursement, à introduire des dispositions assouplies pour les génériques, et à permettre plus de transparence dans les procédures. Merci.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
